Rational design of novel benzisoxazole derivatives with acetylcholinesterase inhibitory and serotoninergic 5-HT


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
20 02 2020
Historique:
received: 27 07 2019
accepted: 30 01 2020
entrez: 22 2 2020
pubmed: 23 2 2020
medline: 13 11 2020
Statut: epublish

Résumé

A rigidification strategy was applied to the preclinical candidate donecopride, an acetylcholinesterase inhibitor possessing 5-HT

Identifiants

pubmed: 32080261
doi: 10.1038/s41598-020-59805-7
pii: 10.1038/s41598-020-59805-7
pmc: PMC7033111
doi:

Substances chimiques

Cholinesterase Inhibitors 0
Isoxazoles 0
Receptors, Serotonin, 5-HT4 158165-40-3
Donepezil 8SSC91326P
Acetylcholinesterase EC 3.1.1.7

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

3014

Références

World Alzheimer Report. The state of the art of dementia research: New frontiers, https://www.alz.co.uk/research/world-report-2018 (2018)
Stelzmann, R. A., Schnitzlein, H. N. & Murtagh, F. R. An English translation of Alzheimer’s 1907 paper, “Uber eine eigenartige Erkankung der Hirnrinde”. Clin. Anat. 8, 429–431, https://doi.org/10.1002/ca.980080612 (1995).
doi: 10.1002/ca.980080612 pubmed: 8713166
Bird, T. D. Genetic aspects of Alzheimer disease. Genet. Med. 10, 231–239, https://doi.org/10.1097/GIM.0b013e31816b64dc (2008).
doi: 10.1097/GIM.0b013e31816b64dc pubmed: 18414205 pmcid: 2690397
Melnikova, I. Therapies for Alzheimer’s disease. Nat. Rev. Drug. Discov. 6, 341–342, https://doi.org/10.1038/nrd2314 (2007).
doi: 10.1038/nrd2314 pubmed: 17539055
Cummings, J. L., Morstorf, T. & Zhong, K. Alzheimer’s disease drug-development pipeline: few candidates, frequent failures. Alzheimer’s Res. Ther. 6, 37, https://doi.org/10.1186/alzrt269 (2014).
doi: 10.1186/alzrt269
Mangialasche, F., Solomon, A., Winblad, B., Mecocci, P. & Kivipelto, M. Alzheimer’s disease: clinical trials and drug development. Lancet Neurol. 9, 702–716, https://doi.org/10.1016/S1474-4422(10)70119-8 (2010).
doi: 10.1016/S1474-4422(10)70119-8 pubmed: 20610346
Morphy, R. & Rankovic, Z. Designed multiple ligands. An emerging drug discovery paradigm. J. Med. Chem. 48, 6523–6543, https://doi.org/10.1021/jm058225d (2005).
doi: 10.1021/jm058225d pubmed: 16220969
Cavalli, A. et al. Multi-target-directed ligands to combat neurodegenerative diseases. J. Med. Chem. 51, 347–372, https://doi.org/10.1021/jm7009364 (2008).
doi: 10.1021/jm7009364 pubmed: 18181565
Lewis, W. G. et al. Click chemistry in situ: acetylcholinesterase as a reaction vessel for the selective assembly of a femtomolar inhibitor from an array of building blocks. Angew Chem Int Ed 41, 1053–1057, 10.1002/1521-3773(20020315)41:6<1053::AID-ANIE1053>3.0.CO;2-4 (2002).
doi: 10.1002/1521-3773(20020315)41:6<1053::AID-ANIE1053>3.0.CO;2-4
Garcia-Palomero, E. et al. Potent beta-amyloid modulators. Neurodegener. Dis. 5, 153–156, https://doi.org/10.1159/000113688 (2008).
doi: 10.1159/000113688 pubmed: 18322376
Inestrosa, N. C., Sagal, J. P. & Colombres, M. Acetylcholinesterase interaction with Alzheimer amyloid beta. Subcell. Biochem. 38, 299–317, https://doi.org/10.1007/0-387-23226-5_15 (2005).
doi: 10.1007/0-387-23226-5_15 pubmed: 15709485
Alvarez, A. et al. Stable complexes involving acetylcholinesterase and amyloid-beta peptide change the biochemical properties of the enzyme and increase the neurotoxicity of Alzheimer’s fibrils. J. Neurosci. 18, 3213–3223, https://doi.org/10.1523/JNEUROSCI.18-09-03213.1998 (1998).
doi: 10.1523/JNEUROSCI.18-09-03213.1998 pubmed: 9547230 pmcid: 6792661
Reyes, A. E. et al. Acetylcholinesterase-Abeta complexes are more toxic than Abeta fibrils in rat hippocampus: effect on rat beta-amyloid aggregation, laminin expression, reactive astrocytosis, and neuronal cell loss. Am. J. Pathol. 164, 2163–2174, https://doi.org/10.1016/S0002-9440(10)63774-1 (2004).
doi: 10.1016/S0002-9440(10)63774-1 pubmed: 15161650 pmcid: 1615768
Agis-Torres, A., Sollhuber, M., Fernandez, M. & Sanchez-Montero, J. M. Multi-Target-Directed Ligands and other Therapeutic Strategies in the Search of a Real Solution for Alzheimer’s Disease. Curr. Neuropharmacol. 12, 2–36, https://doi.org/10.2174/1570159X113116660047 (2014).
doi: 10.2174/1570159X113116660047 pubmed: 24533013 pmcid: 3915347
Kowal, N. M. et al. Novel Approach for the Search for Chemical Scaffolds with Activity at Both Acetylcholinesterase and the α7 Nicotinic Acetylcholine Receptor: A Perspective on Scaffolds with Dual Activity for the Treatment of Neurodegenerative Disorders. Molecules 24, 446, https://doi.org/10.3390/molecules24030446 (2019).
doi: 10.3390/molecules24030446 pmcid: 6384821
Lalut, J., Rochais, C. & Dallemagne, P. Multiple Ligands in Neurodegenerative Diseases, Drug Selectivity – An Evolving Concept in Drug Discovery, Book series “Methods and Principles in Medicinal Chemistry”, Wiley-VCH Publishing House. https://doi.org/10.1002/9783527674381.ch16 (2017).
Lecoutey, C. et al. Synthesis of dual AChE/5-HT4 receptor multi-target directed ligands. Med. Chem. Commun. 3, 627–634, https://doi.org/10.1039/c2md20063e (2012).
doi: 10.1039/c2md20063e
Jourdan, J.-P. et al. Novel benzylidenephenylpyrrolizinones with pleiotropic activities potentially useful in Alzheimer’s disease treatment. Eur. J. Med. Chem. 114, 365–379, https://doi.org/10.1016/j.ejmech.2016.03.023 (2016).
doi: 10.1016/j.ejmech.2016.03.023 pubmed: 27046230
Lalut, J. et al. Novel Multitarget-Directed Ligands Targeting Acetylcholinesterase and σ1 Receptors as Lead Compounds for Treatment of Alzheimer’s Disease: Synthesis, Evaluation, and Structural Characterization of their Complexes with Acetylcholinesterase. Eur. J. Med. Chem. 162, 234–248, https://doi.org/10.1016/j.ejmech.2018.10.064 (2019).
doi: 10.1016/j.ejmech.2018.10.064 pubmed: 30447434
Lecoutey, C. et al. Design of donecopride, a dual serotonin subtype 4 receptor agonist/acetylcholinesterase inhibitor with potential interest for Alzheimer’s disease treatment. Proc. Natl Acad. Sci. US 111, E3825–E3830, https://doi.org/10.1073/pnas.1410315111 (2014).
doi: 10.1073/pnas.1410315111
Bockaert, J., Claeysen, S., Compan, V. & Dumuis, A. 5-HT(4) receptors: history, molecular pharmacology and brain functions. Neuropharmacol. 55, 922–931, https://doi.org/10.1016/j.neuropharm.2008.05.013 (2008).
doi: 10.1016/j.neuropharm.2008.05.013
Matsumoto, M. et al. Evidence for involvement of central 5-HT(4) receptors in cholinergic function associated with cognitive processes: Behavioral, electrophysiological, and neurochemical studies. J. Pharmacol. Exp. Ther. 296, 676–682 (2001).
pubmed: 11181892
Consolo, S., Arnaboldi, S., Giorgi, S., Russi, G. & Ladinsky, H. 5-HT4 receptor stimulation facilitates acetylcholine release in rat frontal cortex. Neuroreport 5, 1230–1232, https://doi.org/10.1097/00001756-199406020-00018 (1994).
doi: 10.1097/00001756-199406020-00018 pubmed: 7919171
Lamirault, L. & Simon, H. Enhancement of place and object recognition memory in young adult and old rats by RS67333, a partial agonist of 5-HT4 receptors. Neuropharmacol. 41, 844–853, https://doi.org/10.1016/S0028-3908(01)00123-X (2001).
doi: 10.1016/S0028-3908(01)00123-X
Russo, O. et al. Design, synthesis, and biological evaluation of new 5-HT4 receptor agonists: application as amyloid cascade modulators and potential therapeutic utility in Alzheimer’s disease. J. Med. Chem. 52, 2214–2225, https://doi.org/10.1021/jm801327q (2009).
doi: 10.1021/jm801327q pubmed: 19334715
Freret, T. Synergistic effect of acetylcholinesterase inhibition (donepezil) and 5-HT4 receptor activation (RS67333) on object recognition in mice. A new hope to design a treatment for Alzheimer’s disease. Behav. Brain Res. 230, 304–308, https://doi.org/10.1016/j.bbr.2012.02.012 (2012).
doi: 10.1016/j.bbr.2012.02.012 pubmed: 22348892
Villalobos, A. et al. Novel Benzisoxazole Derivatives as Potent and Selective Inhibitors of Acetylcholinesterase. J. Med. Chem. 37, 2721–2734, https://doi.org/10.1021/jm00043a012 (1994).
doi: 10.1021/jm00043a012 pubmed: 8064800
Sugimoto, H. et al. Novel Piperidine Derivatives. Synthesis and Anti-Acetylcholinesterase Activity of 1-Benzyl-4-[2-(N-benzoylamino)ethyl]piperidine Derivatives. J. Med. Chem. 33, 1880–1887, https://doi.org/10.1021/jm00169a008 (1990).
doi: 10.1021/jm00169a008 pubmed: 2362265
Brodney, M. A. et al. Identification of Multiple 5-HT
doi: 10.1021/jm300953p pubmed: 22974325
Dubrovskiy, A. V. & Larock, R. C. Synthesis of Benzisoxazoles by the [3 + 2] Cycloaddition of in situ Generated Nitrile Oxides and Arynes. Org. Lett. 12, 1180–1183, https://doi.org/10.1021/ol902921s (2010).
doi: 10.1021/ol902921s pubmed: 20184347 pmcid: 2852127
Chen, C.-y et al. A Divergent and Selective Synthesis of Isomeric Benzoxazoles from a Single N–Cl Imine. Org. Lett. 13, 6300–6303, https://doi.org/10.1021/ol202844c (2011).
doi: 10.1021/ol202844c pubmed: 22067007
Shutske, G. M. A new synthesis of 3-phenyl-1,2-benzisoxazoles: sterically constrained 3-phenyl-1,2-benzisoxazoles by intramolecular carbon:nitrogen bond formation at a hindered carbonyl group. J. Org. Chem. 49, 180–183, https://doi.org/10.1021/jo00175a042 (1984).
doi: 10.1021/jo00175a042
Liu, W. et al. Benzimidazolones: a new class of selective peroxisome proliferator-activated receptor γ (PPARγ) modulators. J. Med. Chem. 54, 8541–8554, https://doi.org/10.1021/jm201061j (2011).
doi: 10.1021/jm201061j pubmed: 22070604
Hoare, D. G. et al. The reaction of hydroxamic acids with water-soluble carbodiimides. A lossen rearrangement. J. Am. Chem. Soc. 90, 1638–1643, https://doi.org/10.1021/ja01008a040 (1968).
doi: 10.1021/ja01008a040 pubmed: 5636802
Mitsunobu, O. & Yamada, M. Preparation of Esters of Carboxylic and Phosphoric Acid via Quaternary Phosphonium Salts. Bull. Chem. Soc. Jpn. 40, 2380–2382, https://doi.org/10.1246/bcsj.40.2380 (1967).
doi: 10.1246/bcsj.40.2380
Udd, S. et al. Copper-catalyzed cyclization of Z-oximes into 3-methyl-1,2-benzisoxazoles. Tetrahedron Lett. 51, 1030–1033, https://doi.org/10.1016/j.tetlet.2009.12.070 (2010).
doi: 10.1016/j.tetlet.2009.12.070
Iranpoor, N. et al. A novel method for the highly efficient synthesis of 1,2-benzisoxazoles under neutral conditions using the Ph3P/DDQ system. Tetrahedron Lett. 47, 8247–8250, https://doi.org/10.1016/j.tetlet.2006.09.120 (2006).
doi: 10.1016/j.tetlet.2006.09.120
Alvaro, G. et al. Dérivés d’hydantoïne utiles en tant qu’inhibiteurs de kv3. WO 2012/076877 A1 (2012).
Ellman, G. L. et al. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol. 7, 88–95, https://doi.org/10.1016/0006-2952(61)90145-9 (1961).
doi: 10.1016/0006-2952(61)90145-9 pubmed: 13726518
Grossman, C. J. et al. Development of a radioligand binding assay for 5-HT4 receptors in guinea-pig and rat brain. Br. J. Pharmacol. 109, 618–624, https://doi.org/10.1111/j.1476-5381.1993.tb13617.x (1993).
doi: 10.1111/j.1476-5381.1993.tb13617.x pubmed: 8358562 pmcid: 2175660
Rochais, C. et al. Novel Multitarget-Directed Ligands (MTDLs) with Acetylcholinesterase (AChE) Inhibitory and Serotonergic Subtype 4 Receptor (5-HT
doi: 10.1021/acs.jmedchem.5b00115 pubmed: 25793650
Cheung, J. et al. Structures of human acetylcholinesterase in complex with pharmacologically important ligands. J. Med. Chem. 55, 10282–10286, https://doi.org/10.1021/jm300871x (2012).
doi: 10.1021/jm300871x pubmed: 23035744
Jones, G., Willett, P. & Glen, R. C. Molecular recognition of receptor sites using a genetic algorithm with a description of desolvation. J. Mol. Biol. 245, 43–53, https://doi.org/10.1016/S0022-2836(95)80037-9 (1995).
doi: 10.1016/S0022-2836(95)80037-9 pubmed: 7823319
Jones, G. et al. Development and Validation of a Genetic Algorithm for Flexible Docking. J. Mol. Biol. 267, 727–748, https://doi.org/10.1006/jmbi.1996.0897 (1997).
doi: 10.1006/jmbi.1996.0897 pubmed: 9126849
Discovery Studio Modeling Environment, release 4.5, San Diego, CA: (2012).
Dubost, E. et al. Synthesis and Structure-Affinity Relationships of Selective High-Affinity 5-HT4 Receptor Antagonists: Application to the Design of New Potential Single Photon Emission Computed Tomography Tracers. J. Med. Chem. 55, 9693–9707, https://doi.org/10.1021/jm300943r (2012).
doi: 10.1021/jm300943r pubmed: 23102207 pmcid: 3509320
Cherezov, V. et al. High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor. Sci. 318, 1258–1265, https://doi.org/10.1126/science.1150577 (2007).
doi: 10.1126/science.1150577
Rivail, L. et al. New insights into the human 5-HT4 receptor binding site:Exploration of a hydrophobic pocket. Br. J. Pharmacol. 143, 361–370, https://doi.org/10.1038/sj.bjp.0705950 (2004).
doi: 10.1038/sj.bjp.0705950 pubmed: 15351779 pmcid: 1575351

Auteurs

Julien Lalut (J)

Normandie Univ, UNICAEN, Centre d'Etudes et de Recherche sur le Médicament de Normandie (CERMN), Caen, France.

Hugo Payan (H)

IGF, Univ. Montpellier, CNRS, INSERM, Montpellier, France.

Audrey Davis (A)

Normandie Univ, UNICAEN, Centre d'Etudes et de Recherche sur le Médicament de Normandie (CERMN), Caen, France.

Cédric Lecoutey (C)

Normandie Univ, UNICAEN, Centre d'Etudes et de Recherche sur le Médicament de Normandie (CERMN), Caen, France.

Rémi Legay (R)

Normandie Univ, UNICAEN, Centre d'Etudes et de Recherche sur le Médicament de Normandie (CERMN), Caen, France.

Jana Sopkova-de Oliveira Santos (J)

Normandie Univ, UNICAEN, Centre d'Etudes et de Recherche sur le Médicament de Normandie (CERMN), Caen, France.

Sylvie Claeysen (S)

IGF, Univ. Montpellier, CNRS, INSERM, Montpellier, France.

Patrick Dallemagne (P)

Normandie Univ, UNICAEN, Centre d'Etudes et de Recherche sur le Médicament de Normandie (CERMN), Caen, France.

Christophe Rochais (C)

Normandie Univ, UNICAEN, Centre d'Etudes et de Recherche sur le Médicament de Normandie (CERMN), Caen, France. christophe.rochais@unicaen.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH